The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP)
Open accessAbstract
Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clinically available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets. Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes. The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin. Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP). We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not. A series of compounds targeting NTCP could inhibit HBV infection. CsA inhibited the binding between NTCP and large envelope protein in vitro . Evaluation of CsA analogs identified a compound with higher anti-HBV potency, having a median inhibitory concentration <0.2 μM. Conclusion : This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatology 2014;59:1726–1737)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, B., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,115
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., & Guguen-Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,282
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V., & Goff, S. P. (1993) · Cell · doi:10.1016/0092-8674(93)90637-6 · Cited by 802
Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation
Palacios, E. H., & Weiss, A. (2004) · Oncogene · doi:10.1038/sj.onc.1208074 · Cited by 714
Ladner, S. K., Otto, M. J., Barker, C. S., Zaifert, K., Wang, G. H., Guo, J. T., Seeger, C., & King, R. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1715 · Cited by 640
Cyclosporin A Suppresses Replication of Hepatitis C Virus Genome in Cultured Hepatocytes
Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., & Shimotohno, K. (2003) · Hepatology · doi:10.1053/jhep.2003.50449 · Cited by 510
Self-citationInhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids
Deres, K., Schröder, C. H., Paessens, A., Goldmann, S., Hacker, H. J., Weber, O., Krämer, T., Niewöhner, U., Pleiss, U., Stoltefuss, J., et al. (2003) · Science · doi:10.1126/science.1077215 · Cited by 508
Cyclophilin B Is a Functional Regulator of Hepatitis C Virus RNA Polymerase
Watashi, K., Ishii, N., Hijikata, M., Inoue, D., Murata, T., Miyanari, Y., & Shimotohno, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.05.014 · Cited by 454
Self-citationSchulze, A., Gripon, P., & Urban, S. (2007) · Hepatology · doi:10.1002/hep.21896 · Cited by 445
Pfefferle, S., Schöpf, J., Kögl, M., Friedel, C. C., Müller, M. A., Carbajo-Lozoya, J., Stellberger, T., von Dall’Armi, E., Herzog, P., Kallies, S., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002331 · Cited by 415
Cited by
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Iwamoto, M., Watashi, K., Tsukuda, S., Aly, H. H., Fukasawa, M., Fujimoto, A., Suzuki, R., Aizaki, H., Ito, T., Koiwai, O., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.052 · Cited by 321
Self-citationPresent and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Kaneko, M., Futamura, Y., Tsukuda, S., Kondoh, Y., Sekine, T., Hirano, H., Fukano, K., Ohashi, H., Saso, W., Morishita, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20987-w · Cited by 26
Self-citationHepatitis B virus receptors and molecular drug targets
Verrier, E. R., Colpitts, C. C., Sureau, C., & Baumert, T. F. (2016) · Hepatology International · doi:10.1007/s12072-016-9718-5 · Cited by 25
Metadata
- Authors
- Watashi, K., Sluder, A., Daito, T., Matsunaga, S., Ryo, A., Nagamori, S., Iwamoto, M., Nakajima, S., Tsukuda, S., Borroto-Esoda, K., Sugiyama, M., Tanaka, Y., Kanai, Y., Kusuhara, H., Mizokami, M., & Wakita, T.
- Venue
- Hepatology
- Published
- 2014-05
- Volume
- 59
- Issue
- 5
- Pages
- 1726-1737
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2123781724
- Cited by
- 266
- References
- 40
- FWCI
- 18.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP). https://app.cochat.ai/papers/10.1002/hep.26982
- The paper
- Watashi, K., Sluder, A., Daito, T., Matsunaga, S., Ryo, A., Nagamori, S., Iwamoto, M., Nakajima, S., Tsukuda, S., Borroto-Esoda, K., Sugiyama, M., Tanaka, Y., Kanai, Y., Kusuhara, H., Mizokami, M., & Wakita, T. (2014). Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP). Hepatology. https://doi.org/10.1002/hep.26982
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.